Health and Human Services officials blocked the publication of a COVID-19 vaccine study slated for a Centers for Disease ...
Moderna’s mRNA-based combination vaccine against both flu and COVID-19 has gotten the green light in Europe—but it continues ...
Investing.com - German biotech company CureVac sued Moderna (NASDAQ:MRNA) in Delaware federal court on Friday, alleging that Moderna’s COVID-19 vaccine Spikevax infringed CureVac patents related to ...
The first participants in the UK and US have received Moderna’s mRNA-1018 vaccine in a phase 3 trial targeting the H5N1 bird flu strain. The study will test safety and immune response in about 4,000 ...
Plus: DOJ drops probe into Powell, paving way for Warsh confirmation; S&P 500 and Nasdaq close at record levels on US-Iran ...
A multi-year effort to address global declines in childhood vaccination has delivered more than 100 million vaccine doses to ...
A report from the CDC finds no secondary cases among passengers and crew who were near infected airline passengers.
Stocks are set to close out April with major gains even as a war in the Middle East is ongoing, and fears around AI ...
TheFly reported on April 9 that B. Riley Financial increased its price target on NVAX from $16 to $18 while maintaining a Buy ...
IFLScience on MSN
In readiness for the next pandemic, human trials begin of an mRNA vaccine for bird flu
An mRNA vaccine for avian influenza, developed by pharma company Moderna, has begun Phase 3 human trials. Building on the ...
Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results